Infinity Bio, Inc.
Joel Credle is a scientific co-founder and director of research and development at Infinity Bio, Inc., where work focuses on characterizing individual antibody repertoires. In addition, Credle co-founded Portal Bioscience LLC, a precision pathology company that develops advanced RNA analysis solutions, including the innovative Lock'n'Roll™ technology. Previously, Credle held positions as a laboratory manager and postdoctoral fellow at Johns Hopkins Medicine, specializing in spatial biology and antibody profiling, and conducted significant research at Georgetown University focusing on the unfolded protein response and Parkinson's disease. Credle earned a Ph.D. in biochemistry and molecular biology from Georgetown University and completed postdoctoral training at The Johns Hopkins University School of Medicine.
This person is not in any teams
This person is not in any offices
Infinity Bio, Inc.
Infinity Bio is a Circulating Antibody Repertoire Profiling service company, leveraging a novel technology, MIPSA (Molecular Indexing of Proteins (or Peptides) by Self Assembly) developed by Dr. H. Ben Larman, a pioneer in this field. Our various antigen libraries provide cost effective, comprehensive and quantitative analyses of antibody responses to infections, vaccinations, self-antigens and allergens. Our proprietary method allows for the rapid and flexible content customization. Infinity Bio can design and create customer specific peptide libraries against any target of choice.